A comparative effectiveness study of lipegfilgrastim in multiple myeloma patients after high dose melphalan and autologous stem cell transplant
G-CSF administration after high-dose chemotherapy and autologous stem cell transplantation (ASCT) has been shown to expedite neutrophil recovery. Several studies comparing filgrastim and pegfilgrastim in the post-ASCT setting concluded that the two are at least equally effective. Lipegfilgrastim (LI...
Gespeichert in:
| Veröffentlicht in: | Annals of hematology 2020-02, Vol.99 (2), p.331-341 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 341 |
|---|---|
| container_issue | 2 |
| container_start_page | 331 |
| container_title | Annals of hematology |
| container_volume | 99 |
| creator | Martino, Massimo Gori, Mercedes Tripepi, Giovanni Recchia, Anna Grazia Cimminiello, Michele Provenzano, Pasquale Fabio Naso, Virginia Ferreri, Anna Moscato, Tiziana Console, Giuseppe Loteta, Barbara Gallo, Giuseppe Alberto Gentile, Massimo Innao, Vanessa Rossi, Marco Morabito, Antonella Vincelli, Iolanda Donatella Mannina, Donato Pitino, Annalisa |
| description | G-CSF administration after high-dose chemotherapy and autologous stem cell transplantation (ASCT) has been shown to expedite neutrophil recovery. Several studies comparing filgrastim and pegfilgrastim in the post-ASCT setting concluded that the two are at least equally effective. Lipegfilgrastim (LIP) is a new long-acting, once-per-cycle G-CSF. This multicentric, prospective study aimed to describe the use of LIP in multiple myeloma patients receiving high-dose melphalan and autologous stem cell transplantation (ASCT) and compare LIP with historic controls of patients who received short-acting agent (filgrastim [FIL]). Overall, 125 patients with a median age of 60 years received G-CSF after ASCT (80 patients LIP on day 1 post-ASCT and 45 patients FIL on day 5 post-ASCT). The median duration of grade 4 neutropenia (absolute neutrophil count [ANC] |
| doi_str_mv | 10.1007/s00277-019-03901-w |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2343396392</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2343396392</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-48d59417191e9d18c0cbc066c4c1de11864079c2fb53845e973b45eb8817cc473</originalsourceid><addsrcrecordid>eNp9kcFu1DAQhi1URLcLL9BDZYlzYBw7a_tYVbRFqsQFzpbjTLKpnDjYDtU-Ba-Mly301rnMSP7mG8k_IZcMPjEA-TkB1FJWwHQFXAOrnt6QDRO8rqBR4oxsQHNdNaXOyUVKjwCsVqJ-R845Uw2XwDfk9zV1YVpstHn8hRT7Ht1xmjElmvLaHWjoqR8XHPrRD9GmPE50nOm0-jwuHul0QB8mS5diwDknavuMke7HYU-7kAqAftlbb2dq547aNQcfhrAe9ThRh97THO2cloLk9-Rtb33CD899S37cfvl-c189fLv7enP9UDkum1wJ1TVaMMk0Q90x5cC1DnY7JxzrkDG1EyC1q_u24Uo0qCVvS2uVYtI5IfmWfDx5lxh-rpiyeQxrnMtJU3PBud5xXReqPlEuhpQi9maJ42TjwTAwxwzMKQNTMjB_MzBPZenqWb22E3b_V_59egH4CUjlaR4wvtx-RfsH3meVcg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2343396392</pqid></control><display><type>article</type><title>A comparative effectiveness study of lipegfilgrastim in multiple myeloma patients after high dose melphalan and autologous stem cell transplant</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Martino, Massimo ; Gori, Mercedes ; Tripepi, Giovanni ; Recchia, Anna Grazia ; Cimminiello, Michele ; Provenzano, Pasquale Fabio ; Naso, Virginia ; Ferreri, Anna ; Moscato, Tiziana ; Console, Giuseppe ; Loteta, Barbara ; Gallo, Giuseppe Alberto ; Gentile, Massimo ; Innao, Vanessa ; Rossi, Marco ; Morabito, Antonella ; Vincelli, Iolanda Donatella ; Mannina, Donato ; Pitino, Annalisa</creator><creatorcontrib>Martino, Massimo ; Gori, Mercedes ; Tripepi, Giovanni ; Recchia, Anna Grazia ; Cimminiello, Michele ; Provenzano, Pasquale Fabio ; Naso, Virginia ; Ferreri, Anna ; Moscato, Tiziana ; Console, Giuseppe ; Loteta, Barbara ; Gallo, Giuseppe Alberto ; Gentile, Massimo ; Innao, Vanessa ; Rossi, Marco ; Morabito, Antonella ; Vincelli, Iolanda Donatella ; Mannina, Donato ; Pitino, Annalisa</creatorcontrib><description>G-CSF administration after high-dose chemotherapy and autologous stem cell transplantation (ASCT) has been shown to expedite neutrophil recovery. Several studies comparing filgrastim and pegfilgrastim in the post-ASCT setting concluded that the two are at least equally effective. Lipegfilgrastim (LIP) is a new long-acting, once-per-cycle G-CSF. This multicentric, prospective study aimed to describe the use of LIP in multiple myeloma patients receiving high-dose melphalan and autologous stem cell transplantation (ASCT) and compare LIP with historic controls of patients who received short-acting agent (filgrastim [FIL]). Overall, 125 patients with a median age of 60 years received G-CSF after ASCT (80 patients LIP on day 1 post-ASCT and 45 patients FIL on day 5 post-ASCT). The median duration of grade 4 neutropenia (absolute neutrophil count [ANC] < 0.5 × 10 [9]/L) was 5 days in both LIP and FIL groups, whereas the median number of days to reach ANC ≥ 0.5 × 10 [9]/L was 10% lower in the LIP than in the FIL group (10 vs 11 days), respectively. Male sex was significantly associated with a faster ANC ≥ 0.5 × 10 [9] L response (
p
= 0.015). The incidence of FN was significantly lower in the LIP than in the FIL group (29% vs 49%, respectively,
p
= 0.024). The days to discharge after ASCT infusion were greater in patients with FN (
p
< 0.001). The study indicates that LIP had a shorter time to ANC recovery and is more effective than FIL for the prevention of FN in the ASCT setting.</description><identifier>ISSN: 0939-5555</identifier><identifier>EISSN: 1432-0584</identifier><identifier>DOI: 10.1007/s00277-019-03901-w</identifier><identifier>PMID: 31853703</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Aged ; Autografts ; Female ; Filgrastim - administration & dosage ; Filgrastim - adverse effects ; Hematology ; Humans ; Male ; Medicine ; Medicine & Public Health ; Melphalan - administration & dosage ; Melphalan - adverse effects ; Middle Aged ; Multiple myeloma ; Multiple Myeloma - mortality ; Multiple Myeloma - therapy ; Neutrophils ; Oncology ; Original Article ; Polyethylene Glycols - administration & dosage ; Polyethylene Glycols - adverse effects ; Prospective Studies ; Sex Factors ; Stem Cell Transplantation ; Stem cells ; Transplants & implants</subject><ispartof>Annals of hematology, 2020-02, Vol.99 (2), p.331-341</ispartof><rights>Springer-Verlag GmbH Germany, part of Springer Nature 2019</rights><rights>Annals of Hematology is a copyright of Springer, (2019). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-48d59417191e9d18c0cbc066c4c1de11864079c2fb53845e973b45eb8817cc473</citedby><cites>FETCH-LOGICAL-c375t-48d59417191e9d18c0cbc066c4c1de11864079c2fb53845e973b45eb8817cc473</cites><orcidid>0000-0002-3987-419X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00277-019-03901-w$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00277-019-03901-w$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31853703$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Martino, Massimo</creatorcontrib><creatorcontrib>Gori, Mercedes</creatorcontrib><creatorcontrib>Tripepi, Giovanni</creatorcontrib><creatorcontrib>Recchia, Anna Grazia</creatorcontrib><creatorcontrib>Cimminiello, Michele</creatorcontrib><creatorcontrib>Provenzano, Pasquale Fabio</creatorcontrib><creatorcontrib>Naso, Virginia</creatorcontrib><creatorcontrib>Ferreri, Anna</creatorcontrib><creatorcontrib>Moscato, Tiziana</creatorcontrib><creatorcontrib>Console, Giuseppe</creatorcontrib><creatorcontrib>Loteta, Barbara</creatorcontrib><creatorcontrib>Gallo, Giuseppe Alberto</creatorcontrib><creatorcontrib>Gentile, Massimo</creatorcontrib><creatorcontrib>Innao, Vanessa</creatorcontrib><creatorcontrib>Rossi, Marco</creatorcontrib><creatorcontrib>Morabito, Antonella</creatorcontrib><creatorcontrib>Vincelli, Iolanda Donatella</creatorcontrib><creatorcontrib>Mannina, Donato</creatorcontrib><creatorcontrib>Pitino, Annalisa</creatorcontrib><title>A comparative effectiveness study of lipegfilgrastim in multiple myeloma patients after high dose melphalan and autologous stem cell transplant</title><title>Annals of hematology</title><addtitle>Ann Hematol</addtitle><addtitle>Ann Hematol</addtitle><description>G-CSF administration after high-dose chemotherapy and autologous stem cell transplantation (ASCT) has been shown to expedite neutrophil recovery. Several studies comparing filgrastim and pegfilgrastim in the post-ASCT setting concluded that the two are at least equally effective. Lipegfilgrastim (LIP) is a new long-acting, once-per-cycle G-CSF. This multicentric, prospective study aimed to describe the use of LIP in multiple myeloma patients receiving high-dose melphalan and autologous stem cell transplantation (ASCT) and compare LIP with historic controls of patients who received short-acting agent (filgrastim [FIL]). Overall, 125 patients with a median age of 60 years received G-CSF after ASCT (80 patients LIP on day 1 post-ASCT and 45 patients FIL on day 5 post-ASCT). The median duration of grade 4 neutropenia (absolute neutrophil count [ANC] < 0.5 × 10 [9]/L) was 5 days in both LIP and FIL groups, whereas the median number of days to reach ANC ≥ 0.5 × 10 [9]/L was 10% lower in the LIP than in the FIL group (10 vs 11 days), respectively. Male sex was significantly associated with a faster ANC ≥ 0.5 × 10 [9] L response (
p
= 0.015). The incidence of FN was significantly lower in the LIP than in the FIL group (29% vs 49%, respectively,
p
= 0.024). The days to discharge after ASCT infusion were greater in patients with FN (
p
< 0.001). The study indicates that LIP had a shorter time to ANC recovery and is more effective than FIL for the prevention of FN in the ASCT setting.</description><subject>Aged</subject><subject>Autografts</subject><subject>Female</subject><subject>Filgrastim - administration & dosage</subject><subject>Filgrastim - adverse effects</subject><subject>Hematology</subject><subject>Humans</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Melphalan - administration & dosage</subject><subject>Melphalan - adverse effects</subject><subject>Middle Aged</subject><subject>Multiple myeloma</subject><subject>Multiple Myeloma - mortality</subject><subject>Multiple Myeloma - therapy</subject><subject>Neutrophils</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Polyethylene Glycols - administration & dosage</subject><subject>Polyethylene Glycols - adverse effects</subject><subject>Prospective Studies</subject><subject>Sex Factors</subject><subject>Stem Cell Transplantation</subject><subject>Stem cells</subject><subject>Transplants & implants</subject><issn>0939-5555</issn><issn>1432-0584</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kcFu1DAQhi1URLcLL9BDZYlzYBw7a_tYVbRFqsQFzpbjTLKpnDjYDtU-Ba-Mly301rnMSP7mG8k_IZcMPjEA-TkB1FJWwHQFXAOrnt6QDRO8rqBR4oxsQHNdNaXOyUVKjwCsVqJ-R845Uw2XwDfk9zV1YVpstHn8hRT7Ht1xmjElmvLaHWjoqR8XHPrRD9GmPE50nOm0-jwuHul0QB8mS5diwDknavuMke7HYU-7kAqAftlbb2dq547aNQcfhrAe9ThRh97THO2cloLk9-Rtb33CD899S37cfvl-c189fLv7enP9UDkum1wJ1TVaMMk0Q90x5cC1DnY7JxzrkDG1EyC1q_u24Uo0qCVvS2uVYtI5IfmWfDx5lxh-rpiyeQxrnMtJU3PBud5xXReqPlEuhpQi9maJ42TjwTAwxwzMKQNTMjB_MzBPZenqWb22E3b_V_59egH4CUjlaR4wvtx-RfsH3meVcg</recordid><startdate>20200201</startdate><enddate>20200201</enddate><creator>Martino, Massimo</creator><creator>Gori, Mercedes</creator><creator>Tripepi, Giovanni</creator><creator>Recchia, Anna Grazia</creator><creator>Cimminiello, Michele</creator><creator>Provenzano, Pasquale Fabio</creator><creator>Naso, Virginia</creator><creator>Ferreri, Anna</creator><creator>Moscato, Tiziana</creator><creator>Console, Giuseppe</creator><creator>Loteta, Barbara</creator><creator>Gallo, Giuseppe Alberto</creator><creator>Gentile, Massimo</creator><creator>Innao, Vanessa</creator><creator>Rossi, Marco</creator><creator>Morabito, Antonella</creator><creator>Vincelli, Iolanda Donatella</creator><creator>Mannina, Donato</creator><creator>Pitino, Annalisa</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><orcidid>https://orcid.org/0000-0002-3987-419X</orcidid></search><sort><creationdate>20200201</creationdate><title>A comparative effectiveness study of lipegfilgrastim in multiple myeloma patients after high dose melphalan and autologous stem cell transplant</title><author>Martino, Massimo ; Gori, Mercedes ; Tripepi, Giovanni ; Recchia, Anna Grazia ; Cimminiello, Michele ; Provenzano, Pasquale Fabio ; Naso, Virginia ; Ferreri, Anna ; Moscato, Tiziana ; Console, Giuseppe ; Loteta, Barbara ; Gallo, Giuseppe Alberto ; Gentile, Massimo ; Innao, Vanessa ; Rossi, Marco ; Morabito, Antonella ; Vincelli, Iolanda Donatella ; Mannina, Donato ; Pitino, Annalisa</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-48d59417191e9d18c0cbc066c4c1de11864079c2fb53845e973b45eb8817cc473</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Aged</topic><topic>Autografts</topic><topic>Female</topic><topic>Filgrastim - administration & dosage</topic><topic>Filgrastim - adverse effects</topic><topic>Hematology</topic><topic>Humans</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Melphalan - administration & dosage</topic><topic>Melphalan - adverse effects</topic><topic>Middle Aged</topic><topic>Multiple myeloma</topic><topic>Multiple Myeloma - mortality</topic><topic>Multiple Myeloma - therapy</topic><topic>Neutrophils</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Polyethylene Glycols - administration & dosage</topic><topic>Polyethylene Glycols - adverse effects</topic><topic>Prospective Studies</topic><topic>Sex Factors</topic><topic>Stem Cell Transplantation</topic><topic>Stem cells</topic><topic>Transplants & implants</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Martino, Massimo</creatorcontrib><creatorcontrib>Gori, Mercedes</creatorcontrib><creatorcontrib>Tripepi, Giovanni</creatorcontrib><creatorcontrib>Recchia, Anna Grazia</creatorcontrib><creatorcontrib>Cimminiello, Michele</creatorcontrib><creatorcontrib>Provenzano, Pasquale Fabio</creatorcontrib><creatorcontrib>Naso, Virginia</creatorcontrib><creatorcontrib>Ferreri, Anna</creatorcontrib><creatorcontrib>Moscato, Tiziana</creatorcontrib><creatorcontrib>Console, Giuseppe</creatorcontrib><creatorcontrib>Loteta, Barbara</creatorcontrib><creatorcontrib>Gallo, Giuseppe Alberto</creatorcontrib><creatorcontrib>Gentile, Massimo</creatorcontrib><creatorcontrib>Innao, Vanessa</creatorcontrib><creatorcontrib>Rossi, Marco</creatorcontrib><creatorcontrib>Morabito, Antonella</creatorcontrib><creatorcontrib>Vincelli, Iolanda Donatella</creatorcontrib><creatorcontrib>Mannina, Donato</creatorcontrib><creatorcontrib>Pitino, Annalisa</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Annals of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Martino, Massimo</au><au>Gori, Mercedes</au><au>Tripepi, Giovanni</au><au>Recchia, Anna Grazia</au><au>Cimminiello, Michele</au><au>Provenzano, Pasquale Fabio</au><au>Naso, Virginia</au><au>Ferreri, Anna</au><au>Moscato, Tiziana</au><au>Console, Giuseppe</au><au>Loteta, Barbara</au><au>Gallo, Giuseppe Alberto</au><au>Gentile, Massimo</au><au>Innao, Vanessa</au><au>Rossi, Marco</au><au>Morabito, Antonella</au><au>Vincelli, Iolanda Donatella</au><au>Mannina, Donato</au><au>Pitino, Annalisa</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A comparative effectiveness study of lipegfilgrastim in multiple myeloma patients after high dose melphalan and autologous stem cell transplant</atitle><jtitle>Annals of hematology</jtitle><stitle>Ann Hematol</stitle><addtitle>Ann Hematol</addtitle><date>2020-02-01</date><risdate>2020</risdate><volume>99</volume><issue>2</issue><spage>331</spage><epage>341</epage><pages>331-341</pages><issn>0939-5555</issn><eissn>1432-0584</eissn><abstract>G-CSF administration after high-dose chemotherapy and autologous stem cell transplantation (ASCT) has been shown to expedite neutrophil recovery. Several studies comparing filgrastim and pegfilgrastim in the post-ASCT setting concluded that the two are at least equally effective. Lipegfilgrastim (LIP) is a new long-acting, once-per-cycle G-CSF. This multicentric, prospective study aimed to describe the use of LIP in multiple myeloma patients receiving high-dose melphalan and autologous stem cell transplantation (ASCT) and compare LIP with historic controls of patients who received short-acting agent (filgrastim [FIL]). Overall, 125 patients with a median age of 60 years received G-CSF after ASCT (80 patients LIP on day 1 post-ASCT and 45 patients FIL on day 5 post-ASCT). The median duration of grade 4 neutropenia (absolute neutrophil count [ANC] < 0.5 × 10 [9]/L) was 5 days in both LIP and FIL groups, whereas the median number of days to reach ANC ≥ 0.5 × 10 [9]/L was 10% lower in the LIP than in the FIL group (10 vs 11 days), respectively. Male sex was significantly associated with a faster ANC ≥ 0.5 × 10 [9] L response (
p
= 0.015). The incidence of FN was significantly lower in the LIP than in the FIL group (29% vs 49%, respectively,
p
= 0.024). The days to discharge after ASCT infusion were greater in patients with FN (
p
< 0.001). The study indicates that LIP had a shorter time to ANC recovery and is more effective than FIL for the prevention of FN in the ASCT setting.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>31853703</pmid><doi>10.1007/s00277-019-03901-w</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-3987-419X</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0939-5555 |
| ispartof | Annals of hematology, 2020-02, Vol.99 (2), p.331-341 |
| issn | 0939-5555 1432-0584 |
| language | eng |
| recordid | cdi_proquest_journals_2343396392 |
| source | MEDLINE; SpringerNature Journals |
| subjects | Aged Autografts Female Filgrastim - administration & dosage Filgrastim - adverse effects Hematology Humans Male Medicine Medicine & Public Health Melphalan - administration & dosage Melphalan - adverse effects Middle Aged Multiple myeloma Multiple Myeloma - mortality Multiple Myeloma - therapy Neutrophils Oncology Original Article Polyethylene Glycols - administration & dosage Polyethylene Glycols - adverse effects Prospective Studies Sex Factors Stem Cell Transplantation Stem cells Transplants & implants |
| title | A comparative effectiveness study of lipegfilgrastim in multiple myeloma patients after high dose melphalan and autologous stem cell transplant |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T18%3A24%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20comparative%20effectiveness%20study%20of%20lipegfilgrastim%20in%20multiple%20myeloma%20patients%20after%20high%20dose%20melphalan%20and%20autologous%20stem%20cell%20transplant&rft.jtitle=Annals%20of%20hematology&rft.au=Martino,%20Massimo&rft.date=2020-02-01&rft.volume=99&rft.issue=2&rft.spage=331&rft.epage=341&rft.pages=331-341&rft.issn=0939-5555&rft.eissn=1432-0584&rft_id=info:doi/10.1007/s00277-019-03901-w&rft_dat=%3Cproquest_cross%3E2343396392%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2343396392&rft_id=info:pmid/31853703&rfr_iscdi=true |